Search
Werewolf Therapeutics Inc
HOWLAdd to Watchlist
0.375USD
+0.013+3.57%
Close 06/24, 16:00（ET）Quotes delayed by 15 min
18.20MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-24The current earnings forecast score of Werewolf Therapeutics Inc is 8.50, ranking 109 out of 388 in the Biotechnology & Medical Research industry. The average price target is 5.50, with a high of 10.00 and a low of 3.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
7.000
Target Price
+1892.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
Werewolf Therapeutics Inc
HOWL
4
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Werewolf Therapeutics Inc's price target?
Analysts forecast that Werewolf Therapeutics Inc's price target is USD 5.50, with the highest forecast at USD 10.00 and the lowest forecast at USD 3.00.
How have Werewolf Therapeutics IncHOWL's recent earnings per share performed?
The market expectation was USD -0.28, while Werewolf Therapeutics IncHOWL's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.26.
What is the analyst rating for Werewolf Therapeutics Inc?
Based on the ratings of Werewolf Therapeutics Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
